On these pages you can check out the latest breast cancer news from BCAC and our member groups. We also provide up-to-date information and links to current breast cancer research and clinical trials. Read latest stories below, or use the filters or the pager below for other stories. Use the form to the right of this to subscribe to our e-News.
New research results show that women with oestrogen receptor positive breast cancer who take the drug tamoxifen for ten years rather than five, have a reduced risk of breast cancer recurring and better overall survival rates.
The findings of the ATLAS (Adjuvant Tamoxifen – Longer Against Shorter) study were presented this week at the renowned San Antonio Breast Cancer Symposium.
A clinical trial comparing a shorter course of partial breast irradiation with standard whole breast irradiation has found that those who received the faster partial treatment were more likely to report side effects and poorer cosmetic outcomes.
New Zealand women were involved in the RAPID clinical trial which compared partial breast irradiation given twice daily over five to eight days with whole breast irradiation given daily over three to five weeks.
The quality of a woman’s social networks — the personal relationships that surround an individual — appear to be just as important as the size of her networks in predicting breast cancer survival, scientists report in the current issue of Breast Cancer Research and Treatment.
New research from the Netherlands shows that the switch from screen film mammography (SFM) to digital mammography (DM) in large, population-based breast cancer screening programs improves the detection of life-threatening cancer without significantly increasing detection of clinically insignificant disease.
New research shows that a 12-month treatment programme of Herceptin is still the best option for women with HER2-positive breast cancer, according to the Breast Cancer Aotearoa Coalition (BCAC).
The latest data from two large clinical trials investigating Herceptin (trastuzumab) was presented at the European Society of Medical Oncology (ESMO) in Vienna, Austria overnight.
New research shows that a 12-month treatment programme of Herceptin is still the best option for women with HER2-positive breast cancer, according to the Breast Cancer Aotearoa Coalition (BCAC).
The latest data from two large clinical trials investigating Herceptin (trastuzumab) was presented at the European Society of Medical Oncology (ESMO) in Vienna, Austria overnight.
The deeper researchers dive into the genetics of breast cancer, the more complicated their discoveries. And the latest, and deepest, dive is no exception.
More than 1,700 post-menopausal women who have been treated with hormonal therapy for more than four years are invited to take part in this clinical trial run by the Australia New Zealand Breast Cancer Trials Group (ANZBCTG).
The study examines whether being given the drug Letrozole a year or more after completing hormonal therapy can prevent or delay breast cancer from recurring in postmenopausal women.